Phio Pharmaceuticals Corp. 8-K Summary
Business Context and Reporting Period
Phio Pharmaceuticals Corp. (PHIO) filed a Current Report on Form 8-K on August 14, 2025. The filing announces the reporting of financial results for the quarter ended June 30, 2025. The company is incorporated in Delaware and trades on The Nasdaq Capital Market.
Key Financial Metrics
The provided filing text serves as a cover document referencing a press release (Exhibit 99.1) for detailed data. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity for the reported period.
Material Changes
No specific material changes versus the prior comparable period are detailed in the text of this 8-K. The document only confirms the timing of the results announcement.
Guidance, Outlook, and Risks
The filing text does not contain management commentary, forward-looking guidance, specific risk factors, or details on contingencies and unusual items. These details are contained within the referenced press release (Exhibit 99.1), which is not included in the input text.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific Q2 2025 revenue, net loss, and cash position figures.
- Verify the company's cash runway and burn rate as disclosed in the full press release.
- Check for any updates on clinical trial progress or regulatory milestones mentioned in the full report.
- Confirm if there were any changes in capital structure or financing activities during the quarter.